Fig. 4: HDAC6 interacts with multiple metabolic and mitochondrial proteins, including fumarate hydratase (FH).
From: Inhibition of HDAC6 alters fumarate hydratase activity and mitochondrial structure
A Schematic of mass-spectrometry-based immunoprecipitation of HDAC6 to determine interacting proteins. B Proportional localisation of interacting proteins above a probability threshold of -logp = 1.3 derived via two-tailed t-test HDAC6 IP vs IgG IP control as assessed using DAVID using the cell component descriptor. Created in BioRender62. C Interactors of HDAC6 compared to IgG rabbit antibody control pulldown and -logp significance value derived via t-test HDAC6 IP vs IgG IP control; a selection of metabolic- and mitochondrial-associated proteins are highlighted in blue. D KEGG pathway analysis of HDAC6-interactors above the probability threshold (t-test HDAC6 IP vs IgG IP control, -logp > 0.3) with the top interactors in the ‘metabolic pathways’ subgroup shown to the right. DAVID combines KEGG pathway terms, such as different metabolic pathways, to reduce term redundancy. E Schematic of global proteomics experiment in MDA-MB-231 or JJN3 cells after 24 h treatment with 10 μM BAS-2. F KEGG pathway and cell component analysis of upregulated (blue) and downregulated (red) proteins after BAS-2 treatment in MDA-MB-231 cells. G Volcano plot of increased and decreased protein expression in MDA-MB-231 cells after BAS-2 treatment (10 µM, 24 h) by proteomics, showing log2(fold change) vs -log(probability [p]) derived via two-tailed t-test. A -log(p) cut-off of 1 is indicated by dotted lines, and a log2(fold change) of -1 or 1. Mitochondrial proteins are highlighted in red, and other significant proteins in blue. Source data are provided as a Source Data file.
